GraniteShares彭博商品整體策略No K-1主動型ETF COMB 深 滬
等待開盤 03-26 09:30:00 美东时间
25.309
+0.024
+0.09%
華盛通- 最 高25.3399
- 今 開24.99
- 成交量 1.66万股
- 最 低 24.99
- 昨 收 25.2855
- 總市值 1.52亿
- 52周最高 26.26
- 市盈率 靜 --
- 換手率 0.28%
- 52周最低 17.7989
- 委 比 0.00%
- 總股本 600.00万
- 歷史最高 26.26
- 量 比 0.11
- 振 幅 1.38%
- 歷史最低 2.5896
- 每 手 1
- 風險率 1.85%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-Relativity Acquisition Says Post-Merger Company To Be Named Instinct Bio Tech Holdings
BRIEF-Relativity Acquisition Says Post-Merger Company To Be Named Instinct Bio Tech Holdings March 25 (Reuters) - Relativity Acquisition Corp ACQC.PK : RELATIVITY ACQUISITION CORP - COMBINED COMPANY TO BE NAMED INSTINCT BIO TECHNICAL COMPANY HOLDINGS, TO LIST ON NASDAQ AS 'BIOT' AND 'BIOTW' Source t
03-25 22:58
BRIEF-Oryzon Announces US Patent Grant Covering Iadademstat Combinations For AML
BRIEF-Oryzon Announces US Patent Grant Covering Iadademstat Combinations For AML March 23 (Reuters) - Oryzon Genomics SA ORY.MC : ANNOUNCES U.S. PATENT GRANT COVERING IADADEMSTAT COMBINATIONS WITH VENETOCLAX KEY COMBINATION FOR THE TREATMENT OF FIRST-LINE ACUTE MYELOID LEUKEMIA (AML) PATENT EXPECTED
03-23 14:36
BRIEF-Siriuspoint Ltd - To Now Operate Through Four Business Areas
BRIEF-Siriuspoint Ltd - To Now Operate Through Four Business Areas March 16 (Reuters) - Siriuspoint Ltd SPNT.N : SIRIUSPOINT LTD - TO NOW OPERATE THROUGH FOUR BUSINESS AREAS SIRIUSPOINT LTD: WILL COMBINE EXISTING NORTH AMERICA & INTERNATIONAL PROGRAMS BUSINESSES INTO ONE SINGLE GLOBAL P&C PROGRAMS D
03-16 19:37
BRIEF-Summit Royalties To Combine With Star Royalties To Create A Scaled, High-Growth Royalty Platform
BRIEF-Summit Royalties To Combine With Star Royalties To Create A Scaled, High-Growth Royalty Platform March 16 (Reuters) - Star Royalties Ltd STRR.V : SUMMIT ROYALTIES TO COMBINE WITH STAR ROYALTIES TO CREATE A SCALED, HIGH-GROWTH ROYALTY PLATFORM SUMMIT ROYALTIES LTD - STAR SHAREHOLDERS TO RECEIVE
03-16 18:37
BRIEF-Yotta Acquisition Terminate Business Combination Agreement With Driveit Financial Auto Group
BRIEF-Yotta Acquisition Terminate Business Combination Agreement With Driveit Financial Auto Group March 11 (Reuters) - Yotta Acquisition Corp YOTA.PK : YOTTA ACQUISITION CORP - ON MARCH 4, TERMINATED BUSINESS COMBINATION AGREEMENT WITH DRIVEIT FINANCIAL AUTO GROUP - SEC FILING YOTTA ACQUISITION COR
03-11 18:24
Iran's Foreign Minister Warns Of 'Inflationary Tsunami' And Historic Oil Deficit Dwarfing 1973 Arab Embargo
Iran warns of an 'inflationary tsunami' and an oil deficit dwarfing the 1973 embargo, as economists predict a $1 trillion US war cost.
03-11 16:43
MORNING BID AMERICAS-Oil's combustible calm
MORNING BID AMERICAS-Oil's combustible calm The opinions expressed here are those of the author, a columnist for Reuters. By Mike Dolan March 10 - What matters in U.S. and global markets today By Mike Dolan , Editor-At-Large, Finance and Markets The fog of war remains thick. Crude oil prices have be
03-10 18:47
BRIEF-Aureus Greenway Holdings Enters Merger Agreement On March 8
BRIEF-Aureus Greenway Holdings Enters Merger Agreement On March 8 March 9 (Reuters) - Aureus Greenway Holdings Inc AGH.O : AUREUS GREENWAY HOLDINGS INC - ENTERS MERGER AGREEMENT ON MARCH 8, 2026 - SEC FILING AUREUS GREENWAY HOLDINGS INC - AUTONOMOUS POWER CORP TO BECOME WHOLLY OWNED SUBSIDIARY OF AU
03-09 19:10
BRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE892
BRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE892 March 9 (Reuters) - IDEAYA Biosciences Inc IDYA.O : IDEAYA BIOSCIENCES ANNOUNCES FIRST-PATIENT-IN FOR PHASE 1 TRIAL OF IDE892, A POTENTIAL BEST-IN-CLASS PRMT5 INHIBITOR FOR MTAP-DELETED SOLID TUMORS, AND PROVIDES MTAP AN
03-09 19:03
BRIEF-U.S. FDA Approves Tecvayli® In Combination With Darzalex Faspro® For Relapsed/Refractory Multiple Myeloma
BRIEF-U.S. FDA Approves Tecvayli® In Combination With Darzalex Faspro® For Relapsed/Refractory Multiple Myeloma March 6 (Reuters) - Halozyme Therapeutics Inc HALO.O : U.S. FDA APPROVES TECVAYLI® IN COMBINATION WITH DARZALEX FASPRO® FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA Source text: ID:nPn3GlMDKa
03-06 21:00
